Segment Information (Details 1) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Geographic information
Product, net	$ 2,712.4	$ 2,622.5	$ 2,639.7	$ 2,380.1	$ 2,502.9	$ 2,539.6	$ 2,466.0	$ 2,309.4	$ 10,354.7	$ 9,817.9	$ 9,188.5
Revenues from anti-CD20 therapeutic programs	415.0	406.5	397.1	340.6	318.2	317.6	349.2	329.5	1,559.2	1,314.5	1,339.2
Other revenues	179.6	$ 48.8	$ 41.6	$ 90.0	50.9	$ 98.6	$ 79.0	$ 87.9	360.0	316.4	236.1
Long-lived assets	3,182.4				2,501.8				3,182.4	2,501.8	2,187.6
U.S
Geographic information
Product, net									7,017.1	7,050.4	6,545.8
Revenues from anti-CD20 therapeutic programs									1,475.6	1,249.5	1,269.8
Other revenues									249.5	224.7	142.0
Long-lived assets	1,226.9				1,272.3				1,226.9	1,272.3	1,296.5
Europe
Geographic information
Product, net									2,844.8	2,237.2	2,165.7
Revenues from anti-CD20 therapeutic programs									0.6	1.9	3.5
Other revenues									67.8	71.5	31.2
Long-lived assets	1,948.2				1,221.1				1,948.2	1,221.1	881.7
Asia
Geographic information
Product, net									160.1	217.3	143.7
Revenues from anti-CD20 therapeutic programs									0.0	0.0	0.0
Other revenues									42.7	20.2	62.9
Long-lived assets	5.2				7.0				5.2	7.0	7.7
Other
Geographic information
Product, net									332.7	313.0	333.3
Revenues from anti-CD20 therapeutic programs									83.0	63.1	65.9
Other revenues									0.0	0.0	0.0
Long-lived assets	$ 2.1				$ 1.4				$ 2.1	$ 1.4	$ 1.7